ARIA Key Stats
- ARIAD Honored with Gold Stevie® Awards as Pharmaceutical Company of the Year at ... 5:00 PM
- Ariad's Iclusig in GIST Phase II Study 3:30 PM
- Ariad's Iclusig in GIST Phase II Study - Analyst Blog Zacks 11:30 AM
- 1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask) Jun 15
- ARIAD Announces Webcast of Its Annual Shareholders Meeting noodls Jun 13
- Ariad Pharmaceuticals Inc. Presents at Goldman Sachs 34th Annual Global Healthca... Jun 11
- 4 Healthcare Stock Stories For Thursday Inspection Jun 11
- Ash Stevens to Manufacture Ponatinib API Marketwired Jun 11
- Ariad Pharma (ARIA) Commences Iclusig Phase 2 Street Insider Jun 11
- ARIAD Announces Initiation of Phase 2 Trial of Ponatinib in Patients with Gastro... Jun 11
ARIA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Ariad Pharmaceuticals is down 0.00% over the last year vs S&P 500 Total Return up 25.82%, Array BioPharma up 54.83%, and Infinity Pharmaceuticals up 40.06%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ARIA
Pro Report PDF for ARIA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ARIA Pro Report PDF
Pro Strategies Featuring ARIA
Did Ariad Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
ARIAD Pharmaceuticals, Inc. is a small pharmaceutical company focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. It has three products: Ridaforolimus, Ponatinib and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. The company is located in Cambridge, Massachusetts. It was established in 1991 by Larry Bock, David Blech and Harvery Berger. It has strong partnerships with Merck.